SAN DIEGO — Last week ResMed reported record revenue for the company's second quarter and six months, ended Dec. 31. Revenue for the quarter was $306 million, an 11 percent increase over the same quarter in 2009, while revenue grew 13 percent to $588 million for the six months.
"We expect the growth of all of our products to continue to benefit from the vastly under-penetrated and growing sleep-disordered breathing market," Kieran T. Gallahue, president and CEO, said in a release.
He added that evidence coming to light shows early intervention in the treatment of SDB may slow or prevent the progression of co-morbidities such as obesity, hypertension, heart disease or drug-resistant hypertension. "The increase in awareness of the role that SDB plays in these costly and debilitating co-morbidities and in the reduction in workplace safety and productivity should continue to be a major driver of market expansion," Gallahue said.
